Equities Analysts Set Expectations for CVKD Q1 Earnings

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Investment analysts at Zacks Research issued their Q1 2026 earnings per share estimates for shares of Cadrenal Therapeutics in a research note issued to investors on Wednesday, April 8th. Zacks Research analyst D. Bautz anticipates that the company will post earnings of ($1.38) per share for the quarter. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($7.59) per share. Zacks Research also issued estimates for Cadrenal Therapeutics’ Q2 2026 earnings at ($1.36) EPS, Q3 2026 earnings at ($1.12) EPS and Q4 2026 earnings at ($1.30) EPS.

CVKD has been the subject of several other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Wednesday, January 21st. HC Wainwright cut their price objective on Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Cadrenal Therapeutics presently has an average rating of “Hold” and an average price target of $13.00.

Cadrenal Therapeutics Trading Up 2.5%

NASDAQ:CVKD opened at $4.97 on Thursday. Cadrenal Therapeutics has a 12 month low of $4.21 and a 12 month high of $17.50. The stock has a 50 day moving average of $6.39 and a two-hundred day moving average of $9.14. The firm has a market cap of $12.46 million, a P/E ratio of -0.74 and a beta of 1.53.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.24).

Institutional Investors Weigh In On Cadrenal Therapeutics

Large investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in shares of Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after purchasing an additional 1,818 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Cadrenal Therapeutics in the third quarter valued at approximately $103,000. DRW Securities LLC purchased a new stake in shares of Cadrenal Therapeutics in the fourth quarter valued at approximately $171,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Cadrenal Therapeutics in the third quarter valued at approximately $274,000. 7.92% of the stock is currently owned by hedge funds and other institutional investors.

Cadrenal Therapeutics News Summary

Here are the key news stories impacting Cadrenal Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $13 price target and published multi‑year EPS forecasts that show losses narrowing (FY2026: ($4.01), FY2027: ($3.91), FY2028: ($2.33)). That less‑negative trajectory versus the consensus may support upside expectations and investor buying interest.
• Positive Sentiment: New data coverage highlights 12‑LOX inhibition as a mechanism to target inflammation tied to obesity and type 2 diabetes — a positive clinical signal for Cadrenal’s pipeline given the large addressable market and potential validation of mechanism. Article Title
• Neutral Sentiment: Zacks Research updated quarterly EPS models (Q1–Q4 2026) projecting roughly ($1.30)–($1.38) per quarter and reiterates the consensus full‑year loss view (≈($7.59)). These are model updates rather than new catalysts and mainly provide short‑term visibility on expected cash burn and dilution needs.
• Negative Sentiment: Cadrenal reported a Q1 quarter (announced March 31) EPS miss — ($1.41) vs. consensus ($1.17) — underscoring current operating losses and the need for financing or milestone progress to materially change the outlook.
• Negative Sentiment: Press coverage framed HC Wainwright’s projections as bearish for the stock price in some outlets, which can amplify selling pressure among short‑term traders despite the firm’s “Buy” call. Article Title

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.